Journal of Advanced Zoology
ISSN: 0253-7214
Volume 45 Issue 01 Year 2024 Page 561:566

Comprehensive Overview Of Sickle Cell Disease: Global Impact, Management Strategies, And Future Directions

Hemraj Singh Rajput[1]*, Mamta Kumari[1], Chitrali Talele[1], Cyril Sajan[1], Varunsingh Saggu[1], Rajesh Hadia[1]

[1]Department of Pharmacy, Sumandeep Vidyapeeth deemed to be University, Piparia, Vadodara, Gujarat-391760, India*

***Corresponding Author:** Dr. Hemraj Singh Rajput,*
**Department of Pharmacy, Sumandeep Vidyapeeth Deemed to be University, Vadodara – 391760, Gujarat, India, Email id: hemrajs119@gmail.com, ORCID: 0000-0002-9783-4479*

Article History

Received: 3/12/2023
Revised: 26/12/2023
Accepted: 10/01/2024

Abstract:

In this comprehensive overview of Sickle Cell Disease (SCD), the discussion delves into the intricacies of this genetic disorder, emphasizing the global health implications and the urgent need for effective management strategies. SCD, characterized by abnormal, crescent-shaped red blood cells, manifests in various health problems, including pain crises, anemia, infections, and strokes. The prevalence of SCD globally has witnessed a significant rise, with the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021 reporting a 41.4% increase in affected individuals from 2000 to 2021.The discussion further highlights the alarming mortality burden associated with SCD, emphasizing the urgency for comprehensive global strategies to prevent and manage the disease. The molecular basis of SCD, particularly the HbS variant leading to sickle cell anemia (SCA), is explored, with SCA remaining the most prevalent and severe form despite numerous variants. Global distribution of SCD is intricately linked to historical malaria prevalence, with regions like sub-Saharan Africa, the Middle East, and India experiencing higher prevalence. However, disparities in diagnosis and treatment between resource-limited and higher-income countries underscore the need for global recognition and intervention. The multifaceted management of SCD involves early diagnosis, preventive measures, and a multidisciplinary approach to complications. While therapies like hydroxyurea, l-glutamine, and stem cell transplant show promise, ongoing research and global awareness are crucial. Government actions are pivotal in establishing effective public health programs, as illustrated by the varying interventions in India, Italy, and the United States. In conclusion, the discussion outlines the complex landscape of SCD, emphasizing the global impact, the need for ongoing research, and the importance of concerted efforts in disease management and prevention. This comprehensive overview serves as a foundation for informed decision-making and future strategies to address the significant burden of SCD worldwide.

Keywords: Sickle cell disease, Anemia, HbS, Beta globin gene,

Introduction

What is sickle cell disease

Sickle cell disease (SCD) constitutes an assortment of hereditary disorders impacting hemoglobin, the protein responsible for transporting oxygen throughout the body. In SCD, a genetic mutation induces a transformation in the shape of red blood cells, causing them to adopt a crescent or "sickle" form.[1] This deviation in the hemoglobin protein, responsible for transporting oxygen in red blood cells, results in a stiff, sickle-shaped configuration under specific conditions. Challenges associated with SCD usually commence at approximately 5 to 6 months of age, giving rise to various health issues, including painful episodes (referred to as sickle cell crises), anemia, swelling in the extremities, susceptibility to bacterial infections, and an elevated risk of stroke.[2] Persistent pain may emerge with advancing age, and individuals in the developed world typically have an average life expectancy ranging from 40 to 60 years.[2] Sickle cell disease (SCD) arises when an individual inherits two abnormal copies of the β-globin gene (HBB), responsible for hemoglobin production, with one copy received from each parent. This gene is located on chromosome 11. Various subtypes exist, determined by the specific mutation present in each hemoglobin gene.[2]

Global Prevalence of sickle cell disease

Sickle cell disease (SCD) represents a worldwide health issue. According to the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021, the global prevalence of SCD witnessed a 41.4% surge, escalating from 5.46 million individuals in 2000 to 7.74 million in 2021.[3] The worldwide number of newborns with SCD rose by 13.7% to 515,000, largely attributed to population expansion in the Caribbean and western and central sub-Saharan Africa. Nevertheless, concerns have been raised about the precision of these statistics.[4]

Global Morbidity and Mortality due to sickle cell disease

Sickle cell disease (SCD) represents a noteworthy global health concern. According to the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021, the worldwide mortality burden of SCD is nearly 11 times greater than previously documented.[4,5] In the year 2021, Sickle Cell Disease (SCD) accounted for 34,400 cause-specific all-age deaths worldwide, yet the overall mortality burden associated with SCD was nearly 11 times higher, reaching 376,000.[4,5] These results underscore the immediate requirement for extensive worldwide strategies to avert and address the challenges posed by Sickle Cell Disease (SCD).

Variant of sickle cell disease and which one is most prevalent

Sickle cell disease (SCD) is a collection of hereditary hemoglobinopathies distinguished by mutations impacting the β-globin chain of hemoglobin.[6] The prevailing and clinically severe manifestation of SCD is sickle cell anemia (SCA), arising from the homozygous acquisition of the sickle cell gene variant (HBB; c.20T>A, p.Glu6Val; OMIM: 141900 (HBB-βS)).[7] This variation is commonly denoted as HbS, arising from the substitution of glutamic acid with valine in the sixth position of the β-globin chain of hemoglobin. This singular mutation induces the synthesis of aberrant hemoglobin, identified as sickle hemoglobin (HbS), which undergoes polymerization in deoxygenated conditions. Consequently, red blood cells become inflexible and adopt a sickle shape, contributing to vaso-occlusion, chronic hemolysis, and a range of complications, significantly impacting disease morbidity.[6]

SCD may also stem from the acquisition of HbS along with various other mutations in the HBB gene. Among these, the most prevalent are the structural β-globin variant βC (referred to as SCD SC) and several β-thalassaemia mutations that result in diminished production of normal β-globin (known as SCD S/β-thalassaemia).[8] Nevertheless, SCD SS or sickle cell anemia (SCA) stands out as the most severe manifestation of SCD and remains the primary subject of extensive research. The reported tally of hemoglobin variants exceeds 3000, with some influencing hemoglobin structure qualitatively (classified as hemoglobinopathies) and others affecting hemoglobin expression levels quantitatively (designated as thalassemias).[7] Despite the myriad variations, sickle cell anemia (SCA) persists as the most widespread type of sickle cell disease (SCD), representing more than 70% of SCD cases globally.[8]

Global Distribution of sickle cell disease

Sickle cell disease (SCD) poses a worldwide health concern, its distribution shaped significantly by historical malaria prevalence. Regions such as sub-Saharan Africa, the Middle East, and India exhibit higher instances of SCD due to the protective advantage conferred by the sickle cell trait against malaria.[9]

Piel and colleagues conducted a study employing surveys and models to assess HbS allele frequencies, creating a global distribution map and projecting that the numbers of infants born with sickle cell anemia (SCA) could

surpass 400,000 by the year 2050.[3] Yet, the distribution of the global SCD burden is uneven. According to the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021, the majority of SCD cases are concentrated in resource-limited regions, notably in the Caribbean and western and central sub-Saharan Africa. These areas have witnessed a substantial rise in SCD births attributed to population growth.[10]
Despite the elevated occurrence of SCD in these areas, the condition frequently goes unrecognized and untreated due to insufficient resources and awareness. Consequently, there is a notable contrast in the morbidity and mortality rates linked to SCD between regions with limited resources and those with higher income levels.[9]

Steps for management of Sickle cell disease from Global health organizations.
SCD is a intricate condition necessitating thorough management approaches, including early detection, preventive measures, and addressing organ damage.[12]
Timely identification is essential for efficiently managing SCD, often facilitated by screening newborns to promptly commence preventative treatments and provide patient education.[9,12]
Mitigation of complications stands as a crucial facet of SCD management, encompassing routine vaccinations, prophylactic antibiotics, and the administration of hydroxyurea—an agent minimizing pain crises and acute chest syndrome frequency. Additionally, transfusions can be employed to avert strokes in high-risk patients. Addressing end-organ damage mandates regular monitoring and intervention for complications, necessitating a collaborative approach involving specialists like hematologists, cardiologists, neurologists, nephrologists, and others.[12]
Supplementing established measures, recent progress in disease-modifying and curative interventions for SCD includes the application of l-glutamine, crizanlizumab, and voxelotor, serving as alternatives or complements to hydroxyurea. Additionally, promising results have emerged from allogeneic hematopoietic stem cell transplants employing matched sibling donors, showcasing elevated five-year event-free and overall survival rates.[12]

Government actions for the management of sickle cell disease
Sickle cell disease (SCD) poses a substantial global health challenge, necessitating thorough management approaches. Governments internationally have acknowledged the imperative requirement for impactful initiatives addressing the prevention and management of SCD.[12,13]
In India, despite the elevated prevalence of SCD, there is an absence of a government-led public health initiative, and limited interventions for the treatment and management of SCD are in place. The review underscores the scarcity of interventions related to SCD and underscores the effectiveness of such interventions in enhancing the well-being of patients, presenting a viable option for implementation in India. It emphasizes the need for governments in regions affected by the disease to consider the insights from available interventions and incorporate them into their respective national programs.[12]
In Italy, a nation with a significant prevalence of hemoglobinopathies and the existence of SCD within the indigenous population, the historical background of the network of hemoglobinopathy centers and their methodology toward addressing SCD has been outlined. The World Health Organization acknowledged hemoglobinopathies, encompassing SCD, as a worldwide public health concern in 2006 and advocated for the establishment of programs by national health systems globally to prevent and manage SCD.[13]
In the United States, the National Heart, Lung, and Blood Institute (NHLBI), in collaboration with the National Institute of Minority Health and Health Disparities, initiated a national research consortium. This consortium aims to identify and evaluate strategies for implementing NHLBI guidelines in a manner that is more rapid, uniform, and broadly applied.[14]
These instances highlight the significance of governmental involvement in addressing Sickle Cell Disease (SCD). Governments have a vital role in creating public health initiatives, allocating funds for research, and enforcing guidelines for both preventing and managing SCD. Nevertheless, there is a pressing need for additional efforts, especially in regions with limited resources where the impact of SCD is most pronounced.

Available medical therapies for the management of sickle cell disease.
The management of Sickle Cell Disease (SCD) encompasses early diagnosis, complication prevention, and the handling of organ damage. Timely diagnosis is critical, often facilitated through newborn screening programs, enabling the prompt initiation of preventative measures and patient education. Complication prevention involves routine vaccinations, prophylactic antibiotics, and the use of hydroxyurea to decrease the frequency of pain crises and acute chest syndrome. Transfusions are employed to prevent strokes in high-risk patients. Addressing organ damage requires a multidisciplinary approach with specialists in hematology, cardiology, neurology, nephrology, and other fields. Advances in disease-modifying therapies such as l-glutamine,

crizanlizumab, and voxelotor, alongside hematopoietic stem cell transplantation, show promise. Despite these strides, further research, clinical trials, and implementation studies are needed to enhance outcomes for SCD. Global health organizations must also acknowledge and implement effective programs for early detection and treatment in resource-poor countries.[11,15]

Discussion

Sickle Cell Disease (SCD) is a hereditary condition impacting hemoglobin, resulting in atypical, crescent-shaped red blood cells. This disorder presents notable health obstacles, including episodes of pain, anemia, infections, and strokes. The worldwide incidence of SCD is increasing, accompanied by considerable morbidity and mortality burdens, underscoring the necessity for thorough management approaches.[16]

The GBD 2021 underscores a 41.4% surge in individuals affected by SCD between 2000 and 2021. However, concerns about data accuracy emphasize the ongoing need for surveillance and data refinement to guide global health policies.[17]

The significant upsurge in SCD mortality, nearly 11 times higher than previously documented, highlights the pressing necessity for worldwide strategies in preventing and managing the condition. These figures reveal a gap in our comprehension and an approach that needs enhancement to effectively address the complexities of SCD on a global level.[5]

Comprehending the molecular foundation of SCD, especially the HbS variant responsible for sickle cell anemia (SCA), holds paramount importance. SCA, emerging from the homozygous acquisition of the HbS variant, stands as the most severe manifestation. Despite the existence of numerous variants, SCA persists as the predominant form, underscoring the necessity for concentrated research and targeted interventions addressing this specific subtype.[18]

The geographical spread of SCD is intricately tied to the past occurrence of malaria, impacting the prevalence of the sickle cell trait. Areas with elevated malaria rates, like sub-Saharan Africa, the Middle East, and India, also demonstrate an increased prevalence of SCD. Nonetheless, disparities exist in the distribution, with resource-limited regions facing heightened morbidity and mortality rates due to challenges in both diagnosing and treating the condition.[17]

Holistic management approaches for SCD encompass timely diagnosis, preventative actions, and a multidisciplinary strategy to address complications. Despite progress in treatments such as hydroxyurea and encouraging curative possibilities, ongoing research and worldwide acknowledgment are essential to enhance results, particularly in regions with limited resources.[19]

Global governments play a pivotal role in instituting public health initiatives, financing research endeavors, and enforcing protocols for SCD. Discrepancies in interventions and awareness are evident, exemplified by the disparity between India's limited interventions and Italy's historical involvement. The endeavors of the United States' National Heart, Lung, and Blood Institute underscore the significance of national research consortiums in expediting the application of guidelines.[20]

Efficient management requires prompt diagnosis, preventative actions, and addressing complications. Treatment options, such as hydroxyurea, l-glutamine, crizanlizumab, voxelotor, and hematopoietic stem cell transplant, show potential. Nonetheless, additional research, clinical trials, and implementation studies are essential to enhance outcomes and address the global disparities in SCD management.[21]

Conclusion

In conclusion, the global perspective on Sickle Cell Disease highlights the need for collaborative efforts, increased awareness, and tailored interventions to address the unique challenges faced by different regions. Continuous research and the implementation of comprehensive strategies are essential to alleviate the burden of SCD on a global scale.

Abbreviations

1. GBD - Global Burden of Diseases, Injuries, and Risk Factors Study
2. HbS - Hemoglobin S
3. NHLBI - National Heart, Lung, and Blood Institute
4. SCA - Sickle Cell Anemia
5. SCD - Sickle Cell Disease

Acknowledgement

We would like to acknowledge Department of Pharmacy, Sumandeep Vidyapeeth Deemed to be University for providing resources and platform for the successful completion of this article.

Author's Contributions

All Authors have contributed equally for the identification of scientific needs and writing of this manuscript.

Funding
Not applicable

Availability of data and materials
Not applicable

Declarations
Ethics approval and consent to participate
Not applicable

Consent for publication
Not applicable

Competing Interests
The authors have no competing interest to declare.

References

1. CDC. Articles about Sickle Cell Disease [Internet]. [cited 2022 Jan 6]. Available from: https://www.cdc.gov/ncbddd/sicklecell/articles.html
2. Brandow AM, Liem RI. Advances in the diagnosis and treatment of sickle cell disease. J Hematol Oncol. 2022;15:202.
3. Global burden of sickle cell disease in 2021 - The Lancet [Internet]. [cited 2022 Jan 6]. Available from: https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(21)00446-7/fulltext
4. Global, regional, and national prevalence and mortality burden of sickle cell disease, 2000–2021: a systematic analysis from the Global Burden of Disease Study 2021.
5. Sickle cell disease is 11 times more deadly than previously recorded [Internet]. [cited 2022 Jan 6]. Available from: https://www.scidev.net/global/disease/news/sickle-cell-disease-is-11-times-more-deadly-than-previously-recorded/
6. Brandow AM, Liem RI. Advances in the diagnosis and treatment of sickle cell disease. J Hematol Oncol. 2022;15:201.
7. Evolutionary history of sickle-cell mutation: implications for global health. Hum Mol Genet. 2021;30(R1):R1192.
8. Chakravorty S, Williams TN. Sickle cell disease: a neglected chronic disease of increasing global health importance. Arch Dis Child. 2015;100:483.
9. Sickle cell disease: a neglected chronic disease of increasing global health importance [Internet]. [cited 2022 Jan 6]. Available from: https://adc.bmj.com/content/100/5/483
10. Sickle Cell Anaemia in a Changing World [Internet]. [cited 2022 Jan 6]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6073801/
11. Advances in the diagnosis and treatment of sickle cell disease [Internet]. [cited 2022 Jan 6]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8268385/
12. Sickle cell disease treatment and management in India: a systematic review of interventional studies [Internet]. [cited 2022 Jan 6]. Available from: https://pubmed.ncbi.nlm.nih.gov/34716067/
13. Current challenges in the management of patients with sickle cell disease – A report of the Italian experience [Internet]. [cited 2022 Jan 6]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6140274/
14. Specifying sickle cell disease interventions: a study protocol of the National Heart, Lung and Blood Institute [Internet]. [cited 2022 Jan 6]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8598781/

15. Recent progress in the treatment of sickle cell disease: an up-to-date review [Internet]. [cited 2022 Jan 6]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8268621/
16. World Health Organization. (2021). Global Burden of Diseases, Injuries, and Risk Factors Study (GBD).
17. Piel FB, et al. Global distribution of the sickle cell gene and geographical confirmation of the malaria hypothesis. Nature Communications. 2017;8:1467.
18. Rees DC, et al. Sickle cell disease. The Lancet. 2019;394(10203):176-188.
19. Kato GJ, et al. Sickle cell disease. Nature Reviews Disease Primers. 2017;3:17010.
20. Ware RE, de Montalembert M, Tshilolo L. Sickle cell disease. The Lancet. 2019;394(10203):1745-1758.
21. National Heart, Lung, and Blood Institute. (2021). Evidence-Based Management of Sickle Cell Disease: Expert Panel Report.